Aptose Biosciences (APS) News Today C$2.22 -0.02 (-0.89%) As of 07/18/2025 04:10 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesBuy This Stock APS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Aptose Biosciences (TSE:APS) Stock Crosses Below 50 Day Moving Average - Should You Sell?July 11, 2025 | marketbeat.comAptose Biosciences Inc. (APS.TO) - Yahoo FinanceJuly 3, 2025 | ca.finance.yahoo.comAptose Biosciences (TSE:APS) Shares Pass Below Fifty Day Moving Average - Here's What HappenedJuly 3, 2025 | marketbeat.comAptose Announces Deferral of Interest Payment - MorningstarJuly 2, 2025 | morningstar.comMAptose Biosciences (TSE:APS) Share Price Passes Below Fifty Day Moving Average - Here's What HappenedJune 25, 2025 | marketbeat.comAptose Biosciences (TSE:APS) Reaches New 52-Week Low - Time to Sell?June 18, 2025 | marketbeat.comAptose Biosciences, Inc.: Aptose Provides Corporate UpdatesJune 17, 2025 | finanznachrichten.deAptose Biosciences (TSE:APS) Share Price Crosses Below 50 Day Moving Average - Here's WhyJune 17, 2025 | marketbeat.comAptose Biosciences (TSE:APS) Stock Price Passes Below 200-Day Moving Average - What's Next?April 19, 2025 | marketbeat.comAptose Biosciences (TSE:APS) Reaches New 1-Year Low - Should You Sell?April 3, 2025 | marketbeat.comAptose Biosciences shares to delist from Nasdaq as of April 2April 2, 2025 | markets.businessinsider.comAptose Biosciences' Shares Tumble Ahead of Nasdaq DelistingApril 2, 2025 | marketwatch.comAptose shares tumble following Nasdaq delisting decisionApril 1, 2025 | in.investing.comAptose Biosciences (TSE:APS) Share Price Passes Below 200-Day Moving Average - What's Next?March 27, 2025 | marketbeat.comAptose Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementsMarch 19, 2025 | nasdaq.comAptose Biosciences (TSE:APS) Stock Price Passes Below 200-Day Moving Average - Should You Sell?March 19, 2025 | marketbeat.comAptose Biosciences (TSE:APS) Sets New 1-Year Low - What's Next?March 4, 2025 | marketbeat.comAlliance Global Partners Upgrades Aptose Biosciences (TSE:APS) to "Strong-Buy"March 2, 2025 | marketbeat.comAptose Biosciences (TSE:APS) Sets New 12-Month High - Here's What HappenedFebruary 27, 2025 | marketbeat.comWhy Is Penny Stock Aptose Biosciences Trading Higher On Thursday?February 20, 2025 | benzinga.comTSX Down 130 Points at Midday With Technology The Biggest DeclinerFebruary 20, 2025 | msn.comAptose's leukemia drug cleared to double clinical trial doseFebruary 20, 2025 | msn.comAptose Biosciences, Inc.: Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialJanuary 10, 2025 | finanznachrichten.deAptose and NCI Collaborate on Cancer Drug TrialsDecember 3, 2024 | markets.businessinsider.comAptose Biosciences Boosts Capital with $8M OfferingNovember 27, 2024 | markets.businessinsider.comAptose Biosciences Announces $8 Million Public OfferingNovember 22, 2024 | markets.businessinsider.comAptose Biosciences Launches TUSCANY Study for AMLNovember 21, 2024 | markets.businessinsider.comAptose Biosciences Inc. (APS.TO)November 19, 2024 | ca.finance.yahoo.comAptose Biosciences, Inc.: Aptose Reports Results for the Second Quarter 2024August 9, 2024 | finanznachrichten.deClosing Bell: Aptose Biosciences Inc up on Wednesday (APS)August 8, 2024 | theglobeandmail.comAptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (APS)July 25, 2024 | theglobeandmail.comAptose Biosciences, Inc.: Aptose Announces Receipt of Deficiency Notice from NasdaqJuly 20, 2024 | finanznachrichten.deClosing Bell: Aptose Biosciences Inc flat on Thursday (APS)May 17, 2024 | theglobeandmail.comBuy Rating for Aptose Biosciences on Tuspetinib’s Promising AML Study and Synergistic PotentialMay 17, 2024 | markets.businessinsider.comAptose Biosciences, Inc.: Aptose Reports Results for the First Quarter 2024May 15, 2024 | finanznachrichten.deAPTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024May 14, 2024 | msn.comAptose Biosciences: Q1 Earnings SnapshotMay 14, 2024 | sfgate.comAptose Biosciences Q1 Net Loss Falls, on Lower ExpensesMay 14, 2024 | finance.yahoo.comAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | seekingalpha.comAptose Biosciences's Earnings: A PreviewMarch 25, 2024 | benzinga.comAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment OptionJanuary 31, 2024 | finance.yahoo.comClosing Bell: Aptose Biosciences Inc flat on Wednesday (APS)December 20, 2023 | theglobeandmail.comAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingDecember 9, 2023 | finance.yahoo.comAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleNovember 30, 2023 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | finance.yahoo.comAptose Reports Results for the Third Quarter 2023November 9, 2023 | finance.yahoo.comAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingNovember 2, 2023 | theglobeandmail.comAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingNovember 2, 2023 | finance.yahoo.comAptose Biosciences, Inc.: Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibOctober 30, 2023 | finanznachrichten.deAptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023October 26, 2023 | finance.yahoo.com Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter. Email Address APS Media Mentions By Week APS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APS News Sentiment▼0.000.59▲Average Medical News Sentiment APS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APS Articles This Week▼00▲APS Articles Average Week Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FRX News Today TH News Today ONC News Today COV News Today MDNA News Today SVA News Today HBP News Today MBX News Today GSD News Today HEM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:APS) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
